A small sample of the patient’s blood will be taken for the Cytovac ALECSAT treatment procedure. Specific cells from the blood will then be isolated to be activated, reinforced and multiplied. Next, the cells will be returned to the patient where they will assume a position as activated fighting cells, targeting cancer cells anywhere in the body.
After a start-up treatment phase with 3 injections, single treatments are repeated at 3-4 months’ intervals in an out-patient clinic. Each treatment consists of a patient’s donation of a blood sample and subsequently 20 days later, the patient is treated with an injection of ALECSAT cells. These treatments will continue till control of the disease is achieved or – at best – there are no traces left of the cancer.
Who can be treated?
Currently, patients can only be treated with ALECSAT in clinical trials at hospitals conducting our trials, whereas manufacturing of the ALECSAT product takes place at Cytovac’s dedicated production laboratories.
Only the patient’s doctor can refer patients to ALECSAT treatments. The company cannot provide treatments outside our clinical programs.
There are indications that ALECSAT will reactivate existing, but suppressed, immune system cells in the patient’s body; and then these cells may also become active in the fight against cancer cells.